| Autor: |
Xing, Gang, Yi, Ce, Dou, Peiyuan, Zhi, Zhengxing, Lin, Bin, Cheng, Maosheng |
| Zdroj: |
Expert Opinion on Therapeutic Patents; March 2021, Vol. 31 Issue: 3 p239-246, 8p |
| Abstrakt: |
ABSTRACTIntroductionThe β2adrenergic receptor (β2AR) is a member of G protein-coupled receptors (GPCRs) that mediate the majority of cellular responses to external stimuli. The agonists can cause smooth muscle relaxation; therefore, many β2AR agonists have been developed especially for the treatment of pulmonary disorders such as asthma and chronic obstructive pulmonary disease (COPD). Many new natural and synthetic compounds have been discovered and developed as novel β2AR agonists over the past 5 years.Areas coveredThis review offers an update for the development of β2AR agonists in the patents published from 2015 to 2020, including new natural and synthetic compounds for the treatment of asthma and COPD. In particular, the latest patents about compounds possessing both muscarinic receptor antagonist and β2adrenergic receptor agonist activity are reviewed.Expert opinionβ2AR agonists have been developed extensively for the treatment of asthma and COPD. In the past 5 years, novel agonists from both natural sources and synthetic methods were intensively developed. Compounds possessing both muscarinic receptor antagonist and β2AR agonist activity represent a new trend in this area because they are possibly able to act together in a synergistic fashion, therefore, relieve the symptoms of patients through two distinct mechanisms. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
